Neurocrine Biosciences, Inc. (NBIX) is a publicly traded company in the Healthcare sector, operating within the Drug Manufacturers - Specialty & Generic industry. The company is headquartered in San Diego, CA, United States. The current CEO is Kyle W. Gano.
NBIX has IPO date of 1996-05-23, 1,800 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $13.13B.
Neurocrine Biosciences, Inc. is a biopharmaceutical company that discovers, develops, and commercializes medications for neurological, endocrine, and psychiatric disorders. The company's marketed products include INGREZZA for tardive dyskinesia, ONGENTYS for Parkinson's disease, ORILISSA for endometriosis, and ORIAHNN for uterine fibroids, alongside a robust pipeline of clinical-stage candidates targeting epilepsy, major depressive disorder, anhedonia, and schizophrenia. Founded in 1992 and headquartered in San Diego, California, Neurocrine has established strategic partnerships with major pharmaceutical companies including Takeda, AbbVie, Mitsubishi Tanabe Pharma, and others to support its development and commercialization efforts across multiple therapeutic areas.
